GenMark Diagnostics to Participate in Upcoming Investor Conferences

CARLSBAD, Calif., Dec. 28, 2020 (GLOBE NEWSWIRE) — GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in two upcoming investor conferences.

GenMark’s management is scheduled to present at the 39^th Annual J.P. Morgan Healthcare Conference in a virtual setting on Tuesday, January 12^th, 2021 at 5:20 p.m. ET. Interested parties can access the live and archived webcast at ir.genmarkdx.com.

GenMark’s management is also scheduled to present at the 23^rd Annual Needham Growth Conference in a virtual setting on Thursday, January 14, 2021 at 5:00 p.m. ET. Interested parties can access the live and archived webcast at ir.genmarkdx.com.

ABOUT GENMARK

GenMark is a leading provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care. Utilizing GenMark’s proprietary eSensor^® detection technology, GenMark’s eSensor XT-8^® and ePlex^® systems are designed to support a broad range of molecular diagnostic tests with compact, easy-to-use workstations and self-contained, disposable test cartridges. GenMark’s ePlex: The True Sample-to-Answer Solution™ is designed to optimize laboratory efficiency and address a broad range of infectious disease testing needs, including respiratory, bloodstream, and gastrointestinal infections.  For more information, visit www.genmarkdx.com.

Investor Relations Contact
Leigh Salvo
(415) 937-5404
ir@genmarkdx.com